KEI Research Note 2020:4 Regeneron failed to disclose BARDA funding in their REGN-COV2 patent Luis Gil Abinader October 20, 2020 Regeneron Pharmaceuticals failed to disclose U.S. government funding in a patent that claims antibodies against COVID-19. The obligation to acknowledge… Continue Reading
On Friday, 16 October 2020, the European Union provided the following perspectives during a three hour debate on the proposed waiver from certain provisions of the TRIPS Agreement for the prevention, containment and treatment of COVID-19 co-sponsored by Eswatini, Kenya,… Continue Reading
On Friday, 16 October 2020, members of the World Trade Organization’s (WTO) TRIPS Council held a three hour debate on the proposal (IP/C/W/669) first tabled by India and South Africa for a waiver from certain provisions of the TRIPS Agreement… Continue Reading
On Friday October 16, 2020, KEI filed a lawsuit (under the Freedom of Information Act) against the Department of Health and Human Services (HHS) and the U.S. Army regarding requests for COVID-19 research and development and procurement contracts awarding hundreds… Continue Reading
United States of America Below are links to copies of the contracts entered into by the US government for technologies to combat the COVID-19 pandemic. KEI is updating this page as we gain access to more contracts, and less redacted… Continue Reading
Through a Freedom of Information Act (FOIA) request, Knowledge Ecology International (KEI) has obtained copies of two vaccine-related contracts entered into by the Biomedical Advanced Research and Development Authority (BARDA), one with AstraZeneca related to COVID-19 vaccines and one with… Continue Reading
Government Funding of COVID-19 Vaccines and Other Medical Technologies DATE: Tuesday, 20 October 2020 TIME: EDT 9:00 to 10:30/UTC: 13:00 to 14:30/CEST: 15:00 to 16:30 CONVENER: Knowledge Ecology International (KEI) REGISTRATION: Please contact thiru [at] keionline.org BACKGROUND: On Tuesday, 20… Continue Reading
On October 5, 2020, KEI organized a panel about government funding of COVID-19 drugs and vaccines at the Global Congress on Intellectual Property and the Public Interest. Although the full Global Congress event was postponed to the year 2021, the… Continue Reading
Regeneron Pharmaceutical recently applied for Emergency Use Authorization of its investigational COVID-19 treatment, REGN-COV2, after Donald Trump said that it cured him of COVID-19, suggesting that Regeneron expects to cash in on the treatment. Taxpayers, however, are funding 80 percent… Continue Reading
(More on KEI’s work on coronavirus here: https://www.keionline.org/coronavirus, and on Moderna, here: https://www.keionline.org/moderna) Oct 8, 2020 Moderna’s statement on intellectual property matters during the COVID-19 pandemic is very good, and should be matched by every manufacturer of a therapeutic, vaccine… Continue Reading